UNSPSC 51361810: Metomidate hydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C13H14N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SKV88232PJ, chemically known as methyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate hydrochloride, but more generally known as metomidate hydrochloride, which bears US NIH Compound Identifier 21474. European Medicines Agency schedules metomidate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08907MIG.

Most nations, for tariff purposes, schedule metomidate hydrochloride under HS 29332990. SMILES: CC(C1CCCCC1)N2CNCC2C(=O)OC.CL.

UNSPSC 51361810 Metomidate hydrochloride is a Commodity code nominally describing a specific pharmaceutical compound, yet recent state and local opportunities tagged under it show little alignment with this narrow scope. The code appears in activity spanning broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs — rather than metomidate-specific sourcing. State and local governments are using this code tag to classify opportunities in emergency medical supplies, pharmacy benefit management, and community health initiatives, suggesting the code serves as a catch-all for pharmaceutical commodities beyond its literal name.

Activity is concentrated in a small number of jurisdictions. Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems (1,900 units of naloxone and 800 systems annually) with a response deadline of July 26, 2023, reflecting quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted a Request for Information in April 2026 exploring direct-to-manufacturer prescription programs without a binding response date, using this phase to gather market intelligence before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Geographic activity is limited to Florida, Texas, and Minnesota–Oregon across recent opportunities. The code shows minimal recent procurement volume and no clear repeat buyers, suggesting either low activity under this specific commodity classification or systematic misalignment between the code's nominal scope and actual state and local buying patterns.